Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
just daydreaming again?
well said, that's what it is, nothing more
From the latest press release:
Dr. Mitchell S. Felder, HALB's Chief Technology Officer and a board-certified attending neurologist stated, "Beta-Amyloid is widely recognized to be a major factor of Alzheimer's Disease. Halberd's unique ability to eradicate Beta-Amyloid, coupled with its eradication of IL-4 and its previous elimination of TNF-Alpha, Phosphorylated-Tau, other target antigens, and inflammatory cytokines from CSF, leads the Company to believe it has achieved unparalleled progress toward slowing or preventing the onset of Alzheimer's Disease and other neurodegenerative diseases, such as Epilepsy, Lou Gehrig's Disease (ALS), PTSD, Traumatic Brain Injury, and Chronic Traumatic Encephalopathy.
Although comparative, competitive data has been difficult to obtain, we believe that this is a truly spectacular result in comparison to any other competitive claimed therapies available anywhere in the world. The best we can determine from competition is that they claim to eliminate only 5-15% of Beta-Amyloid from CSF within a month of expensive treatment."
Only TAU and GLUTAMATE to go to completely eradicate the inflammatory cytokines and building blocks responsible for Alzheimer's, PTSD, CTE, ALS, MS and more. Next steps are partnering with big pharma and/or military (DARPA) and funding to start animal testing.
NOTHING about mergers, bringing in Velocity or SGX, nope
Can someone explain to me why EGYF still has no assets (tangible nor intangible) on its balance sheet, after acquiring Sensortecnics (former holder of all developed IP and patents), as announced November 20th 2020:
https://www.newsfilecorp.com/release/68035/Energy-Finders-Acquires-Sensortecnics
$HALB no dilution since 08/16/2021 (4.5 months)
For me the R&D-contract with Arizona State University (ranked no. 1 in research) took away whatever questions/doubt I had:
https://halberdcorporation.com/wp-content/uploads/2020/09/ASU-K-Fully-Executed.pdf
The principal investigator at ASU for HALB's R&D is Prof. Dr. Qiang (Shawn) Chen (see page 3 Exhibit A of R&D-contract):
https://sols.asu.edu/qiang-chen
Take a look at his research projects, patents etc.
Halberd (through exclusive license MARV enterprises) has its IP fully protected by 3 granted US patents and 16 provisional patent applications.
Halberd is very close to reach full proof-of-concept eradicating the building blocks (Tau, B-amyloid, Ph-Tau) and inflammatory cytokines related to some of the most debilitating neurodegenerative diseases, like Alzheimer's, PTSD, TBI, ALS, MS etc.
Yesterdays PR about the SAMS contract was nice, but especially because it's an indication for what's to come: a contract with DARPA (military) to start animal testing.
Catalysts for the very near term:
- more updates about eradicating GLUTAMATE, IL-4, Tau and B-amyloid from CSF
- up-list to OTCQB (almost ready)
- with full PoC Halberd will try to find partner (DARPA)
- attract funding / government grant
- start animal testing and if successful human testing
Until now NO big pharma company has been successful in treating/curing neurodegenerative diseases, for the very simple reason that medicine CANNOT pass the blood-brain-barrier. Halberd's treatment is based on treating blood/CSF outside the body and then returning it after eradicating the pathogens. IF it works we're looking at a multi-billion dollar company. IF not it's a total loss. Big risk, high reward. Do your DD. Good luck
$HALB + 127% and still incredibly cheap
Dollars coming when partner news and funding to start animal testing, see news today
$HALB + 127% and still incredibly cheap
Dollars coming when partner news and funding to start animal testing, see news today
$HALB 2022 is the breakthrough year for Halberd Corp. This month will tell it all. Preliminary testing almost finished, full proof-of-concept eradicating neurodegenerative diseases from CSF. They need a partner(s) and funding to move on to animal testing. Believe me, with this much test results in hand they will get it. Good luck and have a great year!
Nov. 24th: "We look forward to ambitiously closing out the year strong and delivering for all our clients and stakeholders."
Well, knock me out
A few months ago Halberd issued a press release about a third granted US patent (11186629) treating Cockayne Syndrome (CS), but it attracted little attention. Halberd (licensee MARV Enterprises)already owned 2 granted US patents to protect its extracorporeal treatment, but this third patent is about treating a neurodegenerative disease in an "out-of-the-body" treatment. All experimentation at ASU & YSU at the moment is about treating other neurodegenerative diseases like Alzheimer's, PTSD, CTE, ALS, TBI, MS etc and numerous provisional patent applications have been filed to keep all competition out. Now they have their patent treating CS in the patented extracorporeal treatment using antibodies, they will surely get the patents for treating other diseases the same way. Nobody realises the enormity of the CS patent, but it's the first proof they have completely protected their IP. And mind you, using the antibody/antigen/metallic-moiety/complex in combination with RF/Laser has been protected through prov. patent applications as well.
HALB almost completed the preliminary testing at ASU/YSU and January '22 is key. They need funding/partners to start animal testing. I have no doubt they will succeed. Read some scientific papers on internet by researchers who tried to control inflammatory cytokine levels in cerebral spinal fluid. All total failures. Imagine what happens when dr. Chen from ASU writes his scientific article for publication. Here it is:
Treatment method for Cockayne syndrome
Patent number: 11186629
Abstract: Disclosed is a method for treating of Cockayne Syndrome (CS). Specifically, the invention pertains to a method for the extracorporeal treatment of a body fluid by removing the body fluid from a living body diseased with CS, and applying a targeted antibody either a mammalian target of rapamycin (mTOR) antigen or a death-associated protein 1 (DAP1) in a bodily fluid such as blood, creating an antibody-antigen complex, removing antibody-antigen complex from the bodily fluid, and returning the purified bodily fluid to the CS patient.
Type: Grant
Filed: February 5, 2020
Date of Patent: November 30, 2021
Assignee: HALBERD CORPORATION
Inventor: Mitchell S. Felder
https://patents.justia.com/search?q=mitchell+s.+felder&page=2
Enjoy Christmas and see you in the new year, Bill
$FFZY 0.076 OS 55 million float 9.8 million market cap 4.3 million
Fansfrenzy Corp is the best kept secret in the market, SPAC, and ready for merger / acquisitions. This press release was seen by none:
https://www.prlog.org/12895085-fansfrenzy-corporation-to-pursue-new-strategy.html
* The company (FFZY) also intends to pursue a strategy of acquisition of undervalued assets and properties.
* We plan to be joining forces with new partners in order to maximize the significant potential available in today's marketplace," says president and CEO Bernie Nicholls.
$FFZY 0.076 OS 55 million float 9.8 million
Fansfrenzy Corp is the best kept secret in the market, SPAC, and ready for merger / acquisitions. This press release was seen by none:
https://www.prlog.org/12895085-fansfrenzy-corporation-to-pursue-new-strategy.html
* The company (FFZY) also intends to pursue a strategy of acquisition of undervalued assets and properties.
* We plan to be joining forces with new partners in order to maximize the significant potential available in today's marketplace," says president and CEO Bernie Nicholls.
In a matter of weeks Halberd will reach FULL PROOF OF CONCEPT eradicating the basis for PTSD / CTE / TBI / Alzheimer's / ALS etc from cerebral spinal fluid. No other company has ever succeeded in doing this. The biggest pharmaceuticals failed until now, because medicine can't pass the blood-brain-barrier.
Scientific articles for publication are being prepared and will be published with full PoC. Next phase is animal testing. Halberd will need a partner(s) for funding and support.
Before that this stock will get the attention it needs to take off. Do your DD. And don't forget ALL Halberd IP is protected by full patents or is pending provisional patent applications. Good luck.
Halberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases
Monday, December 20, 2021 8:00 AM
Latest Testing Eliminates Interleukin-2 From Cerebral Spinal Fluid
JACKSON CENTER, PA / ACCESSWIRE / December 20, 2021 / Halberd Corporation (OTC Pink:HALB) has been able to successfully eliminate Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Halberd also successfully replicated its previous successful elimination of each of the inflammatory cytokines listed as complete in the table below. Interleukin-2 is a pro-inflammatory cytokine whose role in Alzheimer's Disease is not very well established, particularly given the multiplicity of bio factors implicated in this devastating disease. It may cause neurodegeneration as well as provide neuroprotection, depending on the level. Maintaining the appropriate level of IL-2, and other inflammatory cytokines in CSF is critical to neuro-health.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "The ability to precisely control the exact level of IL-2 in cerebrospinal fluid may be another important step in halting the progression of Alzheimer's Disease; especially when this ability is combined with the precise control of the concentrations of phosphorylated- Tau, beta-Amyloid and other contributing inflammatory cytokines."
William A. Hartman, Halberd Corporation's Chairman, President & CEO, added, "The significance of these test results is that Halberd's technology can be used to precisely control the levels of inflammatory cytokines and neurotransmitters to inhibit progression, and aid in the treatment, of various neurodegenerative diseases, such as Alzheimer's, Lou Gehrig's Disease, PTSD, CTE and epilepsy, among others. No other approach gives this kind of precise control which is imperative in maintaining a healthy balance of needed elements in the body.
Hartman continued, "This tool has the potential to revolutionize medicine and the treatment of various neurologic and non-neurologic diseases and conditions. The potential of this as an effective treatment for Alzheimer's, PTSD and CTE is a huge step forward for medicine. Additionally, since Alzheimer's Disease shares a number of common inflammatory cytokines with several other diseases, such as cancer, this could lead to an effective treatment for those other diseases which also have eluded removal of the basic causes of the disease."
Hi, the simple answer is yes. Many producers in the US, like this one
https://www.innov-research.com/products/synthetic-human-cerebrospinal-fluid-csf?gclid=Cj0KCQiA8ICOBhDmARIsAEGI6o0u_NvADXu2lh4VEPWszuonu-oCoaxFRRKSp6ge_3_7QUUoDtHGRM4aAhsTEALw_wcB
By the way, all of the natural CSF in the body is replaced every six to eight hours and it is probably filtered through the nervous-system membranes (ependyma)
Pick a random OTC penny stock and look at the long term prediction range......yep > 1.00
FansFrenzy Corporation to pursue a new strategy
Asset management will now be FansFrenzy Corporation's core activity.
By: FANSFRENZY CORPORATION
LAS VEGAS - Nov. 25, 2021
Las Vegas, NV, FansFrenzy Corporation (The "Company") Is announcing today that it has evolved into a company focused on acquisitions and participations in operating businesses. The company (FFZY) also intends to pursue a strategy of acquisition of undervalued assets and properties. This new development is the result of a strategic analysis in which the company concluded that greater shareholder value can be achieved. FansFrenzy Corporation will also continue to pursue the development of its existing IT assets through partners.
"Post-pandemic, there are a great many assets that can be acquired on excellent terms. We plan to be joining forces with new partners in order to maximize the significant potential available in today's marketplace," says president and CEO Bernie Nicholls.
The company (FFZY) has already identified a number of opportunities for growth in the short term.
It should be noted that the company has completed all regulatory requirements to become current and fully reporting with OTC markets.
About FansFrenzy Corporation
FansFrenzy is a company (FFZY) that leverages its position as a publicly traded corporation to acquire and hold undervalued assets as well as to participate and develop those assets. The company relies on a deep bench of corporate and financial expertise to bring out the intrinsic value.
https://www.prlog.org/12895085-fansfrenzy-corporation-to-pursue-new-strategy.html
Think it's the attorney letter, should be filed within 120 days from the fiscal year end date (06/30/2021)
I don't understand your explanation. The profile was verified by MVNT in 07/2021 and that's within the previous 6 months
$FFZY 0.074 OS 56 million Free Float 9.8 million Market Cap 4.1 million
I told you several times BIG things coming here, filed all 2 year old fins and attorney letter to get Current Information, cleaned the balance sheet and now announce new company strategy:
LAS VEGAS - Nov. 25, 2021 - PRLog -- Las Vegas, NV, FansFrenzy Corporation (The "Company") Is announcing today that it has evolved into a company focused on acquisitions and participations in operating businesses. The company (FFZY) also intends to pursue a strategy of acquisition of undervalued assets and properties.
"Post-pandemic, there are a great many assets that can be acquired on excellent terms. We plan to be joining forces with new partners in order to maximize the significant potential available in today's marketplace," says president and CEO Bernie Nicholls."
(CEO Bernie Nicholls is a NHL hockey legend)
Fansfrenzy has a tiny float and with increased interest this stock will fly.
https://www.prlog.org/12895085-fansfrenzy-corporation-to-pursue-new-strategy.html
$FFZY 0.074 OS 56 million Free Float 9.8 million Market Cap 4.1 million
I told you several times BIG things coming here, filed all 2 year old fins and attorney letter to get Current Information, cleaned the balance sheet and now announce new company strategy:
LAS VEGAS - Nov. 25, 2021 - PRLog -- Las Vegas, NV, FansFrenzy Corporation (The "Company") Is announcing today that it has evolved into a company focused on acquisitions and participations in operating businesses. The company (FFZY) also intends to pursue a strategy of acquisition of undervalued assets and properties.
"Post-pandemic, there are a great many assets that can be acquired on excellent terms. We plan to be joining forces with new partners in order to maximize the significant potential available in today's marketplace," says president and CEO Bernie Nicholls."
(CEO Bernie Nicholls is a NHL hockey legend)
Fansfrenzy has a tiny float and with increased interest this stock will fly.
https://www.prlog.org/12895085-fansfrenzy-corporation-to-pursue-new-strategy.html
$FFZY is a SPAC
Fansfrenzy Corp. has an OS of 56 million with 46 million restricted, free float less than 10 million, SP = 0.065 and market cap 3.6 million
Business description until October:
Fansfrenzy's primary focus is the development of assets for the purpose of building operations and bringing to market those assets.
Business description after October:
FansFrenzy (OTC: FFZY) is a company that leverages its position as a publicly traded corporation to acquire and hold undervalued assets as well as to participate and develop those assets and operating businesses.
The balance sheet is clean, only IP vs. notes payable. Check it out.
Potential mergers in:
- BetRegal.net (Fansfrenzy CEO Bernie Nicholls involved)
- Hitlab.com (many cross relations, going public in December, see Stockhouse)
$FFZY is a SPAC
Fansfrenzy Corp. has an OS of 56 million with 46 million restricted, free float less than 10 million, SP = 0.065 and market cap 3.6 million
Business description until October:
Fansfrenzy's primary focus is the development of assets for the purpose of building operations and bringing to market those assets.
Business description after October:
FansFrenzy (OTC: FFZY) is a company that leverages its position as a publicly traded corporation to acquire and hold undervalued assets as well as to participate and develop those assets and operating businesses.
The balance sheet is clean, only IP vs. notes payable. Check it out.
Potential mergers:
- BetRegal.net (Fansfrenzy CEO Bernie Nicholls involved)
- Hitlab.com (many cross relations, going public in December, see Stockhouse)
What else could one wish for......:
(from 05/19/2021)
* The Company has acquired Hi-Alloy Valve, LLC and it expects several other acquisitions or mergers by 4Q21. The Company hopes to announce letters of intent for these new acquisition or merger targets in the future.
https://www.otcmarkets.com/stock/MVNT/news/Movement-Industries-Corporation-OTC-MVNT-Provides-a-Company-Update?id=303826
doesn't sound like announcing mergers
yep, no meat on the bones !!!
Hi, I read everything, so yes I know. I also study scientific reports related to AD, PTSD, TBI etcetera. I’m still very optimistic about HALB’s achievements, that’s why I’m holding
$STGZ
This company with $702 (SEVENHUNDREDTWO DOLLAR) in assets has a market cap of $47,000,000
HILARIOUS
What's next? HALB has to file the annual report on Monday latest. In the notification of late filing they said the delay was due to an ongoing audit. Looks like we get audited financials. Hartman has to file a SEC Form10 to get that long awaited upgrade to OTCQB. It will attract more serious investors, not only pennystock flippers.
Hartman stated several times that reaching Proof of Concept eradicating PTSD/TBI/CTE comes first. That means eradicating from cerebrospinal fluid the inflammatory cytokines IL-6 (see PR, done that), TNF-alpha (in progress) and Glutamate (which is a neurotransmitter). It will be done in a matter of weeks. To me this is an incredible achievement as they succeeded in completely killing IL-6 in CSF in a matter of 10 minutes. Until now no medicine or cure has any significant effect on reducing IL-6 in CSF.
As has been said before the results (written by Dr. Chen/ASU and Dr. Sturrus/YSU) will be published in scientific articles and will draw much attention. Until now HALB is still flying very much under the radar.
With Proof of Concept in hand HALB will try to partner, with big pharma or DARPA. They need funding to start animal testing.
I'm getting more optimistic every time they file a (provisional) patent application, or share more research and testing results. Holding every single share I own.
$FFZY 0.0796
Fansfrenzy Corp. went PINK CURRENT yesterday after filing amended fins. New company will be merged in, they changed the business description.
CEO is former NHL hockey legend Bernie Nicholls who played for the LA Kings and many more. Bernie joined BetRegal recently:
https://betregal.net/br-legends
FFZY has an OS of 55 million shares and a free float of 9.8 million, market cap is $4.4 million
Do your DD and buy some before they announce the merger, good luck
$FFZY 0.0796
Fansfrenzy Corp. went PINK CURRENT yesterday after filing amended fins. New company will be merged in, they changed the business description.
CEO is former NHL hockey legend Bernie Nicholls who played for the LA Kings and many more. Bernie joined BetRegal recently:
https://betregal.net/br-legends
FFZY has an OS of 55 million shares and a free float of 9.8 million, market cap is $4.4 million
Do your DD and buy some before they announce the merger, good luck
PINK CURRENT again, lets hope they keep it that way. Business description changed, take a look at OTC Markets, obviously a merger is coming our way, BIG BIG OPPORTUNITY
First CEO Tony Green told you he was building a multi media platform called Starflic. As we know now there was nothing.
Then they announced buying part of HPIL, but that transaction was cancelled.
So what do we have here? AN EMPTY SHELL WITH A $63 MILLION MARKET CAP,
HAHAHAHAHAHAHAHAHAHA
I told you this would happen. Same old, same old, take a look
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=108778831
I don't want to give you advice what to do, but use your brain
Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer’s Disease
Press Release | 11/01/2021
Elevated levels of IL-6 are believed to be causal factors in PTSD, Chronic Traumatic Encephalopathy, & Alzheimer's Disease.
JACKSON CENTER, PA / ACCESSWIRE / November 1, 2021 / Halberd Corporation (OTC PINK:HALB) successfully eradicated 100% of IL-6 from synthetic cerebral spinal fluid (CSF) in preliminary testing. Through its patented extracorporeal process in combination with its patent-pending laser eradication process, IL-6 was virtually eliminated in as little as three minutes of laser radiation exposure. Elevated levels of IL-6 in CSF have been linked to various neurological disorders.
Dr. Mitchell S. Felder, Chief Technology Officer of Halberd Corporation and a board certified attending neurologist remarked, "The spontaneous production of IL-6 has been shown to be significantly higher in PTSD patients. This has directly correlated with PTSD symptom severity within the PTSD patient group. Practicing psychiatrists have stated they believe that the precisely controlled elimination of IL-6 and other inflammatory cytokines in CSF (cerebrospinal fluid) could be a very major breakthrough against PTSD and suicidal depression. Our recent breakthrough historic achievements with our university partners, position us to achieve that goal in medical practice."
William A. Hartman, Halberd Corporation's Chairman, President & CEO, added, "This is the next step in our march towards finding effective treatments for PTSD, CTE and Alzheimer's Disease. Previously, we successfully eliminated Phosphorylated Tau from CSF, the primary building block of neurofibrillary tangles associated with Alzheimer's Disease. Now that the quality problems have been eliminated from our purchased materials, we expect rapid progress ahead toward the final steps with these historic accomplishments.
"The next steps in our research program include verification testing related to IL-6 elimination from CSF, then moving on to eliminating Tumor Necrosis Factor - Alpha (TNF-a) and ultimately Glutamate from CSF. When we successfully eliminate these pathogens, we will approach the military for endorsement/support. Meanwhile, our longer term objective is to continue to focus on the eradication of the remaining pathogens from CSF and blood plasma related to Alzheimer's Disease, Parkinson's Disease, Lou Gehrig's Disease, Epilepsy and Obesity."
https://www.otcmarkets.com/stock/HALB/news/Halberd-Successfully-Eradicates-IL-6-a-Critical-Factor-in-PTSD-CTE--Alzheimers-Disease?id=328279
Yes, my mistake
November 15th they need to file the quarterly report Q1 2022 and the big question is are the fins AUDITED? If they're serious about OTCQB they are. Let's see
the difference I want to see is the fins are AUDITED, if not the upgrade listing to OTCQB is questionable